Financial Results Reveal Steep Losses and Revenue Collapse

Nutraplus India Ltd. has finally submitted its financial results for the quarter ended June 30, 2020, and the full financial year ended March 31, 2020. The disclosures reveal a stark decline in revenue and significant financial losses.

For the June 2020 quarter, total revenue plummeted to ₹0.04 crore (₹3.88 Lakhs), a staggering 99.88% drop from ₹3,162.40 Lakhs in the prior year. This period also recorded a net loss of ₹1.28 crore (₹127.90 Lakhs).

On an annual basis for FY20, total revenue was ₹106.81 crore (₹10,681.16 Lakhs). However, with expenses reaching ₹154.64 crore (₹15,463.78 Lakhs), the company reported a substantial net loss of ₹47.83 crore (₹4,782.62 Lakhs).

Extreme Delay and Auditor Doubts Raise Serious Questions

The most striking aspect is the extreme delay in these filings. The June 2020 results were only approved in September 2024, over four years past the regulatory deadline. This prolonged non-compliance raises serious questions about the company's adherence to financial reporting standards and its operational capabilities.

Adding to the concerns, auditors could not conduct a full review, citing the company's failure to provide essential financial data. This qualified audit opinion casts significant doubt on the accuracy of the reported figures and the company's overall financial health.

History of Financial Distress and Regulatory Issues

Nutraplus India, established in 1990 as a maker of APIs and specialty chemicals, has a history marked by financial and regulatory difficulties. By February 2020, the company had defaulted on a ₹76.24 crore loan from Saraswat Bank. As of March 31, 2025, it faced accumulated losses totaling ₹62.57 crore. Its net worth has been entirely eroded, and it operates with negative working capital. Auditors have repeatedly voiced concerns about the company's ability to continue operating.

The company has also faced past regulatory action; SEBI previously fined entities involved in manipulating Nutraplus India shares between 2015 and 2017. Its assets were seized under the SARFAESI Act due to its non-performing asset status from FY20.

Disclosure Intensifies Scrutiny on Compliance and Operations

The release of these heavily delayed and qualified results brings renewed attention to Nutraplus India's compliance failures and its precarious financial condition. Investors face considerable uncertainty regarding the company's future operations and any prospect of recovery.

This level of non-compliance could invite further scrutiny from SEBI and stock exchanges, potentially leading to stricter penalties or delisting considerations.

Current operational challenges, including reliance on consultancy and trading activities, suggest difficulties in maintaining core manufacturing operations effectively.

Key Risks for Investors

• Extreme Reporting Delay: A nearly four-year delay in filing financial results represents a significant governance failure.
• Qualified Auditor Opinion: Auditors' inability to perform a comprehensive review due to missing data is a major warning sign.
• Going Concern Doubts: Repeated auditor concerns about the company's ability to continue as a going concern signal severe financial instability.
• Debt Defaults and Asset Seizure: A large loan default and subsequent asset seizure highlight the company's deep financial distress.
• Operational Issues: Reliance on consulting and trading suggests a struggling core business.

Industry Context: Peers Show Stronger Standing

Nutraplus India operates in the API and pharmaceutical ingredients sector. In contrast, major players like Divis Laboratories and Dr. Reddy's Laboratories maintain strong financial health, high credit ratings, and robust borrowing capabilities. Even smaller API manufacturers like Ami Organics Ltd. typically show a much stronger financial position and better adherence to regulatory norms. Other listed peers include Suven Life and Aarti Drugs.

What to Watch For Next

Investors will closely watch for any future filings from Nutraplus India and the regulatory responses from SEBI and stock exchanges. Any communication regarding efforts to resolve debt issues or secure new financing will be critical. The company's ability to restructure or revive its core manufacturing operations, if possible, will also be a key focus.